{"nctId":"NCT00981409","briefTitle":"The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients","startDateStruct":{"date":"2007-07"},"conditions":["Embolism, Pulmonary"],"count":41,"armGroups":[{"label":"Fondaparinux","type":"EXPERIMENTAL","interventionNames":["Drug: Fondaparinux sodium"]},{"label":"unfractionated heparin","type":"OTHER","interventionNames":["Drug: unfractionated heparin (UFH)"]}],"interventions":[{"name":"Fondaparinux sodium","otherNames":["GSK576428"]},{"name":"unfractionated heparin (UFH)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with a confirmed diagnosis (by Multi detector-row CT \\[MDCT\\]) of acute symptomatic PE who are hemodynamically stable (i.e., the condition where anticoagulant therapy alone are indicated) (the time from onset should be no longer than 5 days, and subjects with or without symptomatic DVT are eligible)\n* Age: \\>=20 years\n* Gender: No restriction Female subjects must either be of non-childbearing potential (post-menopausal \\>1 year, hysterectomy, or sterilization), or of childbearing potential, has a negative pregnancy test at screening, and agree to use contraception throughout the study period.\n* Hospitalization status: Subjects who are able to stay at the hospital at least during the initial treatment period.\n* Written informed consent from the subject him/herself or his/her legally acceptable representative. Written informed consent from the subject's legally acceptable representative must be obtained if the subject is incapable of giving consent.\n\nExclusion Criteria:\n\n* Shock or hemodynamic instability\\*.\n\n  \\*: Defined as shock or decreased blood pressure (systolic blood pressure \\<90 mmHg or \\>=40 mmHg) lasting for at least 15 minutes and does not represent hemodynamically unstable conditions due to newly emergent arrhythmia, dehydration or sepsis.\n* Right cardiac function failure detected by echocardiography at screening.\n* Requirement for surgical thrombectomy, catheter intervention and thrombolytic therapy for the current PE.\n* Subjects (for example, with free-floating thrombus in the femoral vein or ilium by MDCT at screening) for whom insertion of inferior vena cava filter is indicated or subjects in whom inferior vena cava filter is present.\n* Prior to entry into the study, therapeutic dosage of anticoagulants for more than 24 hours to treat the current episode.\n* Active, clinically significant bleeding\n* Thrombocytopenia (platelet count \\<10×10⁴/µL at screening)\n* Concurrent conditions with bleeding risk (e.g., ulcer of the gastrointestinal tract, diverticulitis of the gastrointestinal tract, colitis, acute bacterial endocarditis, severe hypertension\\*, or severe diabetes) or bleeding tendency.\n\n  \\*: systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg\n* Severe hepatic disorder\n* Known hypersensitivity to heparin, low-molecular-weight heparin (LMWH) or warfarin\n* Previous history of cerebral hemorrhage\n* Brain, spinal, or ophthalmological surgery within 3 months prior to entry into this study\n* Previous history of Heparin-induced thrombocytopenia\n* Patients for whom anticoagulant therapy is contraindicated or who cannot be taken off anticoagulant therapy due to coexistent condition (e.g. prosthetic heart valve implant).\n* Severe renal disorder (serum creatinine \\>2.0 mg/dL \\[180 µmol/L\\] at screening) in a well hydrated subject\n* Documented hypersensitivity to contrast media\n* Use of any contraindicated drug that cannot be combined with the injection of contrast medium \\[e.g., antihyperglycemic metformin hydrochloride (Glycoran®, Melbin®)\\]\n* Participation in any other therapeutic drug study or a clinical study within 6 months prior to entry into this study\n* Previous participation in a study of GSK576428\n* Drug or alcohol abuse\n* Systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg\n* Recent surgery within 3 days prior to entry into the study\n* Life expectancy \\<3 months\n* Pregnant women, nursing mothers, women who may be pregnant, or women contemplating pregnancy during the study period\n* Others whom the investigator or subinvestigator considers not eligible for the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Participants With Recurrent or New Symptomatic Venous Thromboembolism (VTE)","description":"VTE (pulmonary thromboembolism \\[PE\\] and/or deep vein thromboembolism \\[DVT\\]) was adjudicated blindly by the Central Independent Adjudication Committee of Efficacy (CIACE).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants With Recurrent or New Symptomatic/Asymptomatic Venous Thromboembolism (VTE) (by Type)","description":"VTE (pulmonary thromboembolism \\[PE\\] and/or deep vein thromboembolism \\[DVT\\]) was adjudicated blindly by the Central Independent Adjudication Committee of Efficacy (CIACE).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants With Perfusion Lung Scan Results Scored as Improved, no Change, or Worse","description":"\"Improved,\" \"No change,\" or \"Worse\" was adjudicated blindly by the Central Independent Adjudication Committee of Efficacy (CIACE). Each category is adjudicated by comparison with the perfusion score at baseline by the CIACE.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.6","spread":null},{"groupId":"OG001","value":"90.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Perfusion Score at Baseline and Mean Change From Baseline at Days 5-10","description":"The perfusion score (0: no perfusion; 0.25, 0.5, 0.75, 1: normal) in each of the six lobes of the lung was adjudicated blindly by the Central Independent Adjudication Committee of Efficacy (CIACE). Total perfusion score (r) was calculated as: r = (0.25 x right lower lobe) + (0.12 x right middle lobe) + (0.18 x right upper lobe) + (0.20 x left lower lobe) + (0.12 x lingula) + (0.13 x left upper lobe).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.654","spread":"0.141"},{"groupId":"OG001","value":"0.586","spread":"0.237"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.101","spread":"0.079"},{"groupId":"OG001","value":"0.185","spread":"0.148"}]}]}]},{"type":"SECONDARY","title":"The Percentage of Participants With a Bleeding Event","description":"Bleeding events (major bleeding \\[clinically overt bleeding with: fatality, location in critical organ, a fall in hemoglobin \\>=2 g/dL, or a transfusion \\>=2 units\\], minor bleeding \\[clinically overt bleeding and not adjudicated as major bleeding\\]) were adjudicated blindly by the Central Independent Adjudication Committee of Safety (CIACS).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":31},"commonTop":["Haemorrhage subcutaneous","Constipation","Urinary tract infection","Back pain","Alanine aminotransferase increased"]}}}